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ABSTRACT   
 
BACKGROUND: The merits of ethnomedicine-led approach 
to identify and prioritize anticancer medicinal plants have 
been challenged as cancer is more likely to be poorly 
understood in traditional medicine practices. Nonetheless, it 
is also believed that useful data can be generated by 
combining ethnobotanical findings with available scientific 
studies. Thus, this study combined an ethnobtanical study 
with ligand based in silico screening to identify relevant 
medical plants and predict their anticancer potential based on 
their phytoconstiutents reported in scientific literatures. 
METHODS: First, relevant medicinal plants were identified 
through an ethnobotanical survey. A list of phytochemicals was 
prepared based on literature review of articles which reported on 
the natural products of identified medicinal plants. Then, their 
phytochemicals were subjected to in silico evaluation, which 
included a hybrid score similarity measure, rule of five, Ghose–
Viswanadhan–Wendoloski (GVW)-indices and structural features 
criteria, to predict their anticancer activity and drugability.  
RESULTS: A total of 18 medicinal plants and 265 
phytoconstituents were identified. The natural product pool 
constituted 109(41.13%) terpenoids, 67(25.28%) phenolics, 
29(10.94%) simple and functionalized hydrocarbons, 
26(9.81%) alkaloids, 25(9.43%) glycosides and 9(3.40%) 
compounds belonging to different phytochemical classes. The 
similarity measure using CDRUG identified 34(12.73%) 
phytochemicals with high (p-Value < 0.05) and 35(13.21%) 
with moderate possibility (p-Value < 0.1) of anticancer 
activity. In fact, three of the predicted compounds had the 
same structure with known anticancer compounds 
(HSCORE=1). The 80% GVW-indices based antineoplastic 
drugabilityranges were all mate by 25 of the predicted 
compounds. Predicted compounds were also shown to have 
ring structures and functional groups deemed important for 
anticancer activity.  
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CONCLUSIONS: Given the findings, there is a 
promising anticancer activity by the 
traditionally used medicinal plants and a 
potential for the predicted phytochemicals to be 
pursued as possible hits or me-too drugs. 
KEYWORDS: Ethnobotany, phytochemicals, 




Cancer is a growing public health concern in 
many developing countries. For example, in 
Africa only, there were about 715,000 new 
cancer cases and 542,000 deaths in 2008. These 
figures are also expected to double in the next 
twenty years (1). 
Currently, the lack of access to modern 
cancer care coupled with other factors makes 
many cancer patients of the developing world 
dependent on traditional medicines (2). Given 
the challenges of finding novel anticancer 
medications which are effective, safe, affordable 
and accessible, ethnobotanical and 
ethnopharmacological studies play important 
roles in identifying relevant medicinal plants 
that can be developed further.  
Medicinal plants, which formed the basis of 
traditional medicine practices, have long been 
used by mankind for preventive and curative 
purposes (3,4,5). Historically, ethnobotanical 
studies have resulted in drug discovery for 
numerous ailments including cancer (6,7). 
However, the extrapolation into western 
medicine has no always been direct like in the 
case of vincristine where therapeutic efficacy 
was remotely correlated with the indigenous use 
(8). Apart from the general success of the 
ethnobotanical approach, its values and 
performance vary among different diseases. Its 
scientific importance has also been challenged in 
disease like cancer which are believed to be 
poorly characterized in traditional medicine 
practices (9).    
In spite of ethnobotanical study based 
claims of anticancer activity made by many, the 
National Cancer Institute (NCI) argues that it is 
unlikely for cancer to be established as a single 
disease entity in traditional medicine, 
particularly those internal organ neoplasms such 
as lung, colon, ovarian and prostate cancers (10). 
Such a challenge to the ethnomedicine based 
approach has been further complicated by the 
lack of theory based practice in many of the 
traditional medicine practices which makes the 
information on diseases and plants used less 
reliable. Hence, the ethnobotanincal data 
gathered will in general be inadequate to identify 
relevant medicinal plants for further expensive 
biological investigations (11). 
Still, ethnobotanical reports can provide 
reliable information in external tumors like skin 
cancer, external growths and swellings, tumors 
of the oral cavity, genital tumors despite the 
general issue of establishing cancer as a specific 
diseases in ethnomedicine (10). Besides, their 
relevance in selecting plants for further 
investigation in the area of cancer can be 
enhanced by corresponding the findings with 
existing scientific literature (11). Virtual 
screening methods, which are cost effective, fast 
and reliable, could be utilized to correlate 
findings from existing scientific studies and 
ethnobotanical surveys (12). In retro, such 
methodological combination could also help 
understand the indigenously defined malady in 
terms of its links to cancer.  
To this end, our study combined an 
ethnomedicne study with a ligand based in silico 
method. In doing so, the study aimed at 
providing a scientific basis for the existing 
traditional medicine practice in a complex 
disease like cancer and exploiting its potential 
for drug discovery and development. 
Accordingly, we studied the potential anticancer 
activity and drugability of phytochemicals found 
in plants identified based on an ethnobotanical 
survey. 
 




Study area: The survey was conducted in Harari 
Region. Harari Region is located in eastern part 
of Ethiopia about 500km from Addis Ababa. 
The regions estimated area is about 311.25 
square kilometres. It is located at 09018’33” N 
latitude and 42007’32” E longitude, and situated 
at an elevation of about 1861m above sea level. 
The mean annual rainfall is about 858mm. The 
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region is divided into 19 urban and 17 rural 
kebeles. Harari region is one of the most 
diversified regions of Ethiopia with different 
ethnic and religious groups inhabiting it.   
 
Data collection and analysis: We have 
collected ethnomedicine data on a malady 
locally called ‘Gofla’. It is a term used by the 
local people to express a variety of body part 
swellings, and also claimed to include neoplastic 
tumors.  The survey included 23 respondents 
among which 10 were traditional healers, 6 were 
incense and herbal medicine sellers and 7 were 
elderly persons.Verbal consent was sought from 
interviewees before data collection. Finally, 
taxonomic identification of collected specimens 
was done at Haramaya University herbarium. 
The data were analysed and presented in a table 
containing description of the medicinal plants 
and their use.  
   
In Silico Part 
 
Identification phytochemicals in the 
medicinal plants: After taxonomic 
identification, a review was conducted to 
determine the different phytoconstituents 
reported in each herb. The search for relevant 
articles was made on Google Scholar 
(http://scholar.google.com/) and 
PubMed(https://www.ncbi.nlm.nih.gov/pubmed)
. Once the search was finalized, reported 
phytochemicals were extracted and compiled in 
to a list. 
 
Prediction of anticancer activity: The 
anticancer activity was studied in silicousing a 
web server named Cancer Drug (CDRUG; 
http://bsb.kiz.ac.cn/CDRUG/).CDRUG uses 
relative frequency-weighted fingerprint and a 
hybrid score(HSCORE) to determine the 
similarity between compound of interest and 
those found within its dataset. It computesp-
values for the similarity measures based on 
which anticancer activity is predicted as highly 
possible, possible and less possible. It has the 
ability to hit 65% positive results at a rate 0.05 
false-positive (13). Since it requires the 
Simplified Molecular Input Line Entry String 
(SMILES) of compounds to be investigated, 
PubChem(https://pubchem.ncbi.nlm.nih.gov/) 
and FoodDB(http://foodb.ca/) databases were 
used as sources of required entries. For a small 
number of compounds, line strings were also 
determined on Molinspiration Cheminformatics 
(www.molinspiration.com/). Ultimately, the 
SMILES and a single word name of the query 
compounds were fed in to CDRUG as inputs for 
the prediction analysis.  
 
Evaluation of general and anticancer drug-
likeness: The analysis to discriminate between 
drugable and non-drugable compounds was done 
only for those compounds predicted to have 
anticancer activity. Initially, they were evaluated 
against Lipinski’s rule (14). Next, Ghose–
Viswanadhan–Wendoloski (GVW) drug like 
indices, which are based on the distribution of 
physicochemical properties and chemical 
components in Comprehensive Medicinal 
Chemistry (CMC) database, were used for the 
evaluation. Among the indices determined for 
general drug likeness and seven disease based 
drug classes, we used the physicochemical 
property based ranges (Preferred and Qualifying 
range) particularly set for antineoplastic 
drugability. We also determined the presence of 
relevant functional groups, as determined by 
Ghose et al (15). All required physicochemical 
properties were determined online by 
Molinspiration (www.molinspiration.com/) and 
E-Dragon(http://www.vcclab.org) using 
SMILES and SDF files as required (16). Finally, 
additional structure features of drug-likeness like 
aromatic rings and proportion of heavy atoms 




The initial ethnobotanical survey gathered 
information from twenty three participants, and 
we were able to identify eighteen different 
medicinal plants and five additives used in the 
preparation of medications for swellings in 
different parts of the body, locally called 
‘Gofla’. The plants mainly belonged to 
Asteraceae and Lamiaceae families. The most 
commonly reported plant was 
Senecionevadensis (9) followed by 
Hydnorajohannis and ‘Shefewein’ each being 
reported eight times by respondents. 
Viscumschimperi, Aloe vera and Brassica 
carinata were the third most frequently reported 
medicinal plants.These plants were used to treat  
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Scientific name  Family  Local name  Use description  Swelled body 
part 




662 Hydnora johannis Hydnoraceae DechMerech -Root of Hydnorajohannis are crushed, boiled with water containing 
exocarp/peel of coffee beans and taken orally 
-Shefewein are crushed, boiled with water containing exocarp/peel of 
coffee beans and taken orally 
-Leaves of Senecioabyssinicusare boiled with water containing 
exocarp/peel of coffee beans and taken orally 
- All three plants mentioned above and roots ofEchinopskebericho are 




**   Shefewein 
1146 Senecio nevadensis Asteraceae Balkutel 
2970 Echinops kebericho Asteraceae Kebericho 
7491 Punica granatum Punicaceae Roman -Rind of the fruit is boiled with water and taken orally Abdomen  
9836 Boswellia 
papyrifera 
Burseraceae Habeket -Gum of the plant is macerated in cold water which forms a thick gel 




Santacaceae Muka- Gofela -Stems are crushed, rolled in a small paper like a cigar and smoked. 
The smoke is held around the neck area and exhaled  
Neck   
2075 Aloe harlana Aloeaceae Rate  - Leaves are expressed and filtrate is taken orally  Abdomen   
2775 Brassica carinata Cruciferae Goman-zer -Seeds are crushed, mixed with honey and taken orally. Also applied 
on breast externally  
Breast 
3227 Zaleya pentandra Aizoaceae Wachara-haree -Leaves are boiled with water and taken orally  Liver  
5960 Sphaeranthus 
suaveolens 
Asteraceae Hadeshshadye -Leaves and stems Sphaeranthussuaveolensare crushed, the  juice 








Lamiaceae Mukawakwak -leaves and stems of  the plant is crushed, boiled with water and taken 
orally  
-leaves and stems are powdered, mixed in cold water and applied 




Rutaceae Geda -Leaves and stems are crushed and boiled with water containing 
exocarp/peel of coffee beans and taken orally  
Neck, breast, 
abdomen 
697 Amaranthus spp Amaranthaceae AnenaKuti -Leafs and stems are boiled with tea or milk and then taken orally Neck, breast, 
abdomen 
7643 Eulophia petersii Orchidaceae Shenkurtagara -Bulbs are cooked and eaten  Abdomen 
7850 Viscum schimperi Loranthac Digelo -Leaves and stems are crushed, boiled with water and taken orally  Neck, breast, 
abdomen 
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swellings in parts like the neck, the breast, the 
abdomen and the liver. Leaves and stems, which 
collectively accounted for over 60%, were 
commonly used parts. The use of roots was also 
relatively common, 3(15.8%). The four additives 
were exocarp/peel of coffee beans, water, tea, milk 
and honey. The medications were almost always 
administered orally that may indicate 
understanding of the need for systemic 
administration in treating the tumours (Table 1). 
Even though we initially determined 18 medicinal 
plants, only 14 were taxonomically identified. The 
following review managed to retrieve relevant 
literatures for 13 of the identified species and a 
total of 265 phytochemicals. This initial pool 
included 109(41.13%) terpenes/terpenoids, 
67(25.28%) phenolic compounds, 29(10.94%) 
saturated and unsaturated hydrocarbons, 
26(9.81%) alkaloids, 25(9.43%) glycosides, and 
9(3.40%) other phytochemicals. Their analysis on 
CDRUG predicted 34 (12.73%) of them as highly 
likely to possess anticancer activity (P-value < 
0.05). Another 35(13.21%) of the 
phytoconstituents were also predicted to have 
possible anticancer activity (P-value < 0.1). The 
mean logGI50 (the 50% growth inhibition 
concentration) values of the natural products with 
high possibility of antineoplastic activity ranged 
from -4.681 to -5.981, and the logGI50 of those 
constituents with possible bioactivity ranged from 
-5.000 to -7.914. Among the 34 compounds 
predicted to have high possibility of anticancer 
activity, 17(14 triterpenoids, 2 sesquterpenoid & 1 
diterpenoid) were terpenes/terpenoids 9 (1 
phenolic acid, 6 flavanoids, 1 phenylpropanoid &1 
anthraquinone) were phenolic compounds, 5 (4 
isoquinolones & 1 indole) were alkaloids, 2 were 
steroidal glycosides, and 1 was unclassified. 
Similarly, the possible group contained 17(4 
monoterpenoids, 11 sesquiterpenoids & 2 
diterpenoids) terpenes/terpenoids, 14(5 phenolic 
acids, 4 flavanoids, 2 stilbenoids & 1 
phenylpropanoid) phenolic compound, 3(2 
isoquinolone &1 indole) alkaloids, and 1 phenolic 
glycoside.  
         The drugability of the compounds was 
assessed by combing methods that are based on 
physicochemical properties and structural features. 
First, the general drug-likeness of predicted 
phytochemicals was evaluated using the Lipinski’s 
rule of five. The rule states that most of orally 
absorbed drugs possess hydrogen bond donors 
(HBDs) ≤ 5, hydrogen bond acceptors (HBAs) ≤ 
10, a molecular weight (MW) ≤ 500 Daltons and 
octanol/water partition coefficient (LogP) value of 
≤ 5 (18). The analysis of these molecular 
properties for the highly possible compounds have 
shown that 13(38.2%) and 18(52.9%) of the 
predicted active compounds have no or one 
violation, respectively. Among the possible 
compounds, 16(45.7%) have no violation and 
16(45.7%) have only one violation. Thirty-one of 
the highly possible compounds and thirty of the 
possible compounds have molecular weight less 
than 500 Daltons. The LogP distribution showed 
that 16(47.1%) of the highly possible compounds 
and 24 (68.6%) of the possible compounds were 
under the limit set by the Lipinski rule. Over 
seventy-five percent of predicted compounds on 
both groups possessedfive HBDs or fewer. Over 
ninety percent of the predicted active compounds 
were with ten HBAs or fewer (Figure 1).  
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Figure 1: Drug-likeness of predicted phytochemicals based on Lipinski’s rule of five (1A): Distribution of 
predicted phytochemicals based on the number of violations of the rule of five. (1B,1C,1D): Distribution of 
molecular weight, LogP, number of hydrogen bond donors and number of hydrogen bond acceptors of 
predicted phytochemicals. 
According to Ghose et al.,Ghose–CrippenLogP 
(ALogP), Ghose–Crippen molar refractivity 
(AMR), molecular weight (MW) and number of 
atoms (nA) can be used collectively to determine 
drug-likeness (19). Their analysis showed that 
none of the predicted active compounds fulfilled 
all the criteria of the preferred range. The 
individual violations of the preferred range 
constituted 40(58.0%), 39(56.5%), 22(31.9), 
47(68.1%) for MW, ALogP, AMR and nA, 
respectively. Unlike the preferred range, a total of 
25 phytochemicals both from the highly possible 
[12(35.3%)] and the possible [13(37.1%)] lists fall 
within the limits set for the qualifying range 
(Figure 2). 
Analysis of rings and functional groups 
showed that 18(52.9%) of the highly possible 
natural products were with two or more of the 
structural features believed to be important for 
drug-likeness. A similar feature was also observed 
in 19(54.3%) of the possible phytochemicals. 
Heterocyclic rings (mainly aliphatic), alcohol and 
benzene were the most common groups in both 
sets of phytoconstituents. Functional groups like 
carboxyester, keto, aliphatic amine and hetero 
aromatic rings were also found in the predicted 
compounds. Nonetheless, no carboxamide group 
was found in any of the compounds. Besides, over 
seventy percent of the predicted phytochemicals 
were found to possess proportion of heavy atoms, 
i.e. a ratio of non-hydrocarbon atoms to the 
number of all non-hydrogen atoms (R-value), 
between 0.05 and 0.50 (Figure 2).  
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Figure 2: Antineoplastic drug-likeness of predicted phytochemicals according to GVW-indices based ranges. (2A, 2B): 
Bar graphs of number of violations to the preferred and qualifying antineoplastic drug ranges by predicted 
phytochemicals. (2C, 2D): Distribution of molecular weight, Ghose–CrippenLogP, Ghose–Crippen molar refractivity 
and number of atoms (nA) of predicted phytochemicals. (2E): Histogram of relevant structural features found in the 
predicted phytochemicals 
DISCUSSION  
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Traditional medicines, which are largely based on 
the use of plants as drugs, are estimated to be used 
approximately by 80% of the population in 
developing countries as primary healthcare 
sources (20). This estimation may be higher for 
diseases like cancer where treatment options are 
usually inaccessible and/or unaffordable. Given 
this magnitude of use, it is in the public’s health 
interest to identify these medicinal plants and 
generate scientific evidence on their efficacy. 
Hence, we conducted an ethnobotanical survey 
followed by a ligand based computational study to 
identify and evaluate their therapeutic value 
claimed in the traditional practice.  
Medicinal plants have played a huge role in 
anticancer drug discovery. They contributed to the 
discovery of around 48% of all anticancer drugs 
between 1940 and 2002 (21). Many of these plants 
were used in different traditional medicines for 
ages. Although the importance ethnobotanical 
directed drug discovery efforts have been 
challenged due to their limited impact in the last 
two decades and unsatisfactory performance when 
compared to random screening approach, such 
approaches still play a useful role in drug 
discovery programs (22).We do believe that an in 
silico method imparts cost and time effectiveness 
given the limitations of the approach while 
harnessing its potential. Accordingly, a ligand-
based in silico approach was used to identify 
phytochemicals as possible hits or me-too drugs in 
addition to scientifically evaluating the herbal 
medicines traditional use. 
According to a study on traditional medicine 
database, CDRUG was able to identify 5278 
compound out of which 75% were similar to 
approved anticancer drugs (Tanimoto coefficient ≥ 
0.70, MACCS fingerprint), and the top 346 
compounds it identified were identical to 
compounds with proven anticancer activity on 60 
cell lines (23). Given such performance of 
CDRUG, our finding can be taken as a 
preliminary evidence of anticancer activity by 
many of the medicinal plants used for treating 
‘Gofla’. Among the 13 species whose 
phytochemicals were analysed, 11(84.6%) 
contained one or more compounds predicted to 
possess high possibility of anticancer activity. One 
or more phytoconstituents predicted to have a 
moderate possibility for bioactivity were also 
found in 12 (92.3%) of medicinal plants. The use 
of these plants in combinations in the traditional 
medicine practice may also enhance their activities 
by increasing both the amount and type of the 
predicted anticancer compounds in the 
preparations. Species such as Punica granatum, 
Boswellia papyrifera, Viscum schimperi and 
Fagara usambarensis contained higher number of 
compounds predicted to have anticancer activity in 
both categories. Nonetheless, these species should 
not be considered as having superior anticancer 
activity over the rest since the number of 
phytochemicals analysed for each of species 
varies.    
Drug discovery is a challenging, time 
consuming and costly process. In small molecule 
drug development, the initial emphasis is largely 
on efficacy which makes addressing the issue of 
drugability secondary. This practice often leads to 
high failure rates and development costs (17). 
Hence, we also assessed the general and 
antineoplastic drugability of relevant 
phytochemicals in addition to a similarity based 
prediction of anticancer activity. The initial 
evaluation using Lipinski’s rule of five determined 
that over ninety percent of the predicted 
compounds to be drug-like as they contained no or 
only oneviolation (24). 
Since the Lipinski rule serves little to 
discriminate between drugs and non-drugs other 
than predicting oral bioavailability, we used 
additional rules that not only test the general drug-
likness but also the antineoplastic drugability (24). 
The physicochemical properties used by Ghoseet 
al, are classified into two sets of ranges. The first 
one is the preferred range (50%) defined as the 
range within the qualifying range occupied by 
approximately 50% of the antineoplastic drugs in 
CMC database. Compounds with ALogP 0.0-3.7, 
AMR 60-107, MW 258-388 andnA 30-55 belong 
to this range. The fact that we found no compound 
of interest, which meet all the 50% criteria, may 
indicate the lack of novel chemical entities in our 
finding as this range is considered an efficient way 
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of searching for new drugs. The second one is the 
qualifying range which covers 80% of the drugs 
and provides the advantage of reducing the chance 
of missing anticancer drug-like compounds. 
Compounds with ALogP -1.5-4.7, AMR 43-128, 
MW 180-475 and nA 21- 63 are included to this 
range (25). Contrary to the preferred range, we 
found 25 chemicals meeting all the criteria of this 
range. This augments the result from CDRUG in 
proving the anticancer activity of the predicted 
phytochemicals.  
Structural features are important criteria in 
the assessment of drug-likeness. The combined 
presence of certain structures like benzene ring, 
heterocyclic rings (both aliphatic and aromatic), 
keto, alcohol, aliphatic amine, carboxamide and 
carboxyester groups, may signal antineoplastic 
and other drug likenesses (15). Many of the 
bioactive natural products determined in this study 
contained all these features, which may be 
considered as an indication of good drugability in 
addition to efficacy. Aromatic rings either alone or 
combined with non-aromatic rings are relevant for 
antineoplastic activity, structural features 
possessed by over half of the predicted 
compounds. In addition, over two-third of 
identified phytochemicals possessed proportion of 
heavy atoms (R- value) between 0.05–0.50, which 
is thought to indicate good antineoplastic drug-
likeness. However, the fact that only 3(4.3%) of 
the predicted compounds contained an amine (-
NH2) group, a functional group thought to be 
beneficial for anticancer activity, may undermine 
the prediction of being both efficacious and 
drugable(17). Generally, the evaluation based on 
important structural features found at least half of 
the predicted compounds to have good anticancer 
drugability.  
Our investigation of both anticancer efficacy 
and drugability, which combined a hybrid score 
based similarity measure, rule of five, GVW- 
drug-likeness indices and structural features 
criteria, have determined a number of possible 
antineoplastic phytochemicals. These compounds 
have the potential for further study as possible hits 
or me-too drug sources of cancer treatment. Given 
the distribution of these phytochemicals, there is 
also a potential for many of the medicinal plants to 
possess anticancer activity. As far as the 
traditional medicine practice is concerned, there is 
an in silico evidence to suggest anticancer efficacy 
of the traditional treatments. The efficacy of these 
treatments may be even higher due to the practice 
of combining the medicinal plants, which can 
increase both the amount and type of predicted 
anticancer compounds within preparations.  
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